Moleculin Biotech, Inc. Sale of Stock, Consideration Received on Transaction
Moleculin Biotech, Inc. (MBRX) had Sale of Stock, Consideration Received on Transaction of $8.20 million as of 2018-02-16, per its 10-Q filed 2018-11-13.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2018-11-13
- 2018-02-16: Sale of Stock, Consideration Received on Transaction $8.20M.
| Period end | Sale of Stock, Consideration Received on Transaction |
|---|---|
| 2018-02-16 | $8.20M 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |